Literature DB >> 9178154

Movement disorders in Japanese encephalitis.

U K Misra1, J Kalita.   

Abstract

Movement disorders in Japanese encephalitis (JE), although reported, have not been analyzed systematically. In this study, we report an analysis of movement disorders in 14 out of 17 JE patients, correlated with the radiological findings. All patients had at least a four fold rise of IgG antibodies against JE in a haemagglutination inhibition test. The patients' ages ranged between 2 and 54 years and 4 of them were women. Extrapyramidal signs, such as hypokinesia, hypophonia and masking of the face, were present in all patients by the first month as the patients came out of the coma-except for 1 patient. Eight patients had axial and 3 tongue dyskinesia; rigidity was present in 6 and tremor in 2 patients. At 3 months, these symptoms improved considerably in 6 patients. Cranial CT scan revealed thalamic involvement in 10, which was bilateral in 9 patients. Two patients had brain stem and one had cerebellar involvement. Cranial MRI was carried out in 9 patients and revealed additional findings in lentiform nucleus, midbrain and pons in 3 each and cerebellum in 4 patients. Bilateral thalamic involvement on MRI was seen in all the patients, including two patients whose CT scans were normal. SPECT studies using 99mTc-ECD revealed bilateral thalamic hypoperfusion in all (n = 7) and frontal hypoperfusion in 3 patients. In JE, movement disorders are common and may be due to thalamic involvement in isolation or in combination with basal ganglia or midbrain or both.

Entities:  

Mesh:

Year:  1997        PMID: 9178154     DOI: 10.1007/s004150050090

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  25 in total

1.  Japanese encephalitis.

Authors:  T Solomon; N M Dung; R Kneen; M Gainsborough; D W Vaughn; V T Khanh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

Review 2.  Non-traumatic coma in children.

Authors:  F J Kirkham
Journal:  Arch Dis Child       Date:  2001-10       Impact factor: 3.791

Review 3.  West Nile encephalitis.

Authors:  Tom Solomon; Mong How Ooi; David W C Beasley; Macpherson Mallewa
Journal:  BMJ       Date:  2003-04-19

4.  MR findings in Murray Valley encephalitis.

Authors:  Lloyd Einsiedel; Evelyn Kat; Janakan Ravindran; John Slavotinek; David L Gordon
Journal:  AJNR Am J Neuroradiol       Date:  2003-08       Impact factor: 3.825

5.  Spectrum of movement disorders in encephalitis.

Authors:  U K Misra; J Kalita
Journal:  J Neurol       Date:  2010-07-17       Impact factor: 4.849

6.  Cerebrospinal fluid catecholamine levels in Japanese encephalitis patients with movement disorders.

Authors:  U K Misra; J Kalita; S Pandey; V K Khanna; G Nagesh Babu
Journal:  Neurochem Res       Date:  2005-09       Impact factor: 3.996

7.  A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice.

Authors:  Na Li; Zhe-Rui Zhang; Ya-Nan Zhang; Jing Liu; Cheng-Lin Deng; Pei-Yong Shi; Zhi-Ming Yuan; Han-Qing Ye; Bo Zhang
Journal:  NPJ Vaccines       Date:  2020-08-05       Impact factor: 7.344

Review 8.  Recent advances in Japanese encephalitis.

Authors:  Tom Solomon
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

9.  An evaluation of the usefulness of neuroimaging for the diagnosis of Japanese encephalitis.

Authors:  N M Dung; Lance Turtle; W K Chong; N T Mai; T T Thao; T T Thuy; R Kneen; N H Phu; B Wills; J Farrar; K Das; Tom Solomon
Journal:  J Neurol       Date:  2009-12       Impact factor: 4.849

10.  Involvement of nigrostriatal pathway in Japanese encephalitis with movement disorders: evidence from 99mTc-TRODAT-1 and 123I-IBZM SPECT imagings.

Authors:  Chang-Hsu Liao; Zaodung Ling; Chung-Hsing Chou; Wen-Sheng Huang; Jong-Chyou Denq; Jiann-Chyun Lin; Cheng-Yu Chen; Chia-Jung Chang; Giia-Sheun Peng
Journal:  Mol Imaging Biol       Date:  2009-06-23       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.